Cytokinetics (CYTK) announced the appointment of James Daly to its Board of Directors effective August 19, 2025. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company’s Board of Directors. Most recently, Daly served as the Chief Commercial Officer at Incyte Corporation (INCY)
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ Aficamten Study: A Potential Breakthrough for Pediatric Heart Health
- Cytokinetics: Promising Outlook with Aficamten’s Regulatory Progress and Strong Financial Health
- Cytokinetics’ Earnings Call: Progress Amid Challenges
- Buy Rating for Cytokinetics Driven by Regulatory Reviews and Strategic Trials for Drug Afi
- Cytokinetics price target lowered to $77 from $80 at Citi